US hospitals turn down #remdesivir, limit use to sickest #COVID-19 patients - CNA
“I am not terribly impressed with the study,” said Dr Adarsh Bhimraj, an infectious disease specialist at the Cleveland Clinic. He said he remains “sceptical” about using remdesivir in patients with moderate COVID-19, especially given the price.
Dr Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital in Boston, said his centre has stayed focused on using remdesivir for the narrower population of seriously ill patients who need supplemental oxygen.
“No one wants to be in a position of making treatment decisions based on drug availability,” he said.
Houston Methodist Hospital is holding off on broader use of remdesivir, and instead is stockpiling it in case the pandemic flares up in winter – typically the peak season for respiratory illness.
“At this point, we are buying far more than we are using because we are unsure about what will happen at the end of September,” said Katherine Perez, infectious disease pharmacist at Houston Methodist.
There is no evidence that COVID-19 patients admitted to the hospital for a day or two due to an underlying health issue, like diabetes or high blood pressure, would benefit from the drug, she added.
Mark Sullivan, associate chief pharmacy officer at Nashville’s Vanderbilt University Hospitals and Clinics, said his institution also did not expand remdesivir use based on the newer JAMA data.
“We have kept our treatment protocol the same,” he said.